Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice
Open Access
- 17 January 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Abstract
Macrophages are a major population of immune cells in solid cancers, especially colorectal cancers. Tumor-associated macrophages (TAMs) are commonly divided into M1-like (tumor suppression) and M2-like (tumor promotion) phenotypes. Vasoactive intestinal peptide (VIP) is an immunoregulatory neuropeptide with a potent anti-inflammatory function. Inhibition of VIP signaling has been shown to increase CD8+ T cell proliferation and function in viral infection and lymphoma. However, the role of VIP in macrophage polarization and function in solid tumors remains unknown. Here, we demonstrated that conditioned medium from CT26 (CT26-CM) cells enhanced M2-related marker and VIP receptor (VPAC) gene expression in RAW264.7 macrophages. VIP hybrid, a VIP antagonist, enhanced M1-related genes but reduced Mrc1 gene expression and increased phagocytic ability in CT26-CM-treated RAW264.7 cells. In immunodeficient SCID mice, VIP antagonist alone or in combination with anti-PD-1 antibody attenuated CT26 tumor growth compared with the control. Analysis of tumor-infiltrating leukocytes found that VIP antagonist increased M1/M2 ratios and macrophage phagocytosis of CT26-GFP cells. Furthermore, Vipr2 gene silencing or VPAC2 activation affected the polarization of CT26-CM-treated RAW264.7 cells. In conclusion, the inhibition of VIP signaling enhanced M1 macrophage polarization and macrophage phagocytic function, resulting in tumor regression in a CT26 colon cancer model.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K17053, 18H03191)
This publication has 48 references indexed in Scilit:
- The prognostic landscape of genes and infiltrating immune cells across human cancersNature Medicine, 2015
- Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate–protein kinase a pathwayLiver Transplantation, 2013
- Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipientsBlood, 2013
- The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal CancerPLOS ONE, 2012
- VIP–PACAP System in ImmunityAnnals of the New York Academy of Sciences, 2006
- The Significance of Vasoactive Intestinal Peptide in ImmunomodulationPharmacological Reviews, 2004
- Vasoactive intestinal peptide and its relationship to tumor stage in colorectal carcinoma: an immunohistochemical studyJournal of Gastroenterology, 2002
- Inhibition of IFN-γ-Induced Janus Kinase-1-STAT1 Activation in Macrophages by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating PolypeptideThe Journal of Immunology, 2000
- A VIP hybrid antagonist: From developmental neurobiology to clinical applicationsCellular and Molecular Neurobiology, 1995
- Polypeptide with Broad Biological Activity: Isolation from Small IntestineScience, 1970